Glucagon-like peptide-1 (GLP-1) receptor agonists, the active ingredient in weight-loss drugs like tirzepatide and semaglutide, promote satiation even before a person begins his or her meal, a new study suggests.
The findings, published in Science on Thursday, indicate that the drug influences a brain pathway in the hypothalamus, causing a person to feel full when he or she encounters food.
“Humans injected with GLP-1 receptor agonists experienced a higher degree of satiation merely from seeing or smelling food, even before ingesting it,” one of the authors, Dr. Joon Seok Park, said in a video about the study.
GLP-1 receptor agonists have been on the market since 2017 when the U.S. Food and Drug Administration (FDA) approved semaglutide Ozempic as a treatment for Type 2 diabetes. In 2021, the FDA approved Wegovy, another semaglutide, for chronic weight management in adults suffering from at least one weight-related health condition, like high blood pressure, Type 2 diabetes, or high cholesterol. […]
— Read More: www.theepochtimes.com
What Would You Do If Pharmacies Couldn’t Provide You With Crucial Medications or Antibiotics?
The medication supply chain from China and India is more fragile than ever since Covid. The US is not equipped to handle our pharmaceutical needs. We’ve already seen shortages with antibiotics and other medications in recent months and pharmaceutical challenges are becoming more frequent today.
Our partners at Jase Medical offer a simple solution for Americans to be prepared in case things go south. Their “Jase Case” gives Americans emergency antibiotics they can store away while their “Jase Daily” offers a wide array of prescription drugs to treat the ailments most common to Americans.
They do this through a process that embraces medical freedom. Their secure online form allows board-certified physicians to prescribe the needed drugs. They are then delivered directly to the customer from their pharmacy network. The physicians are available to answer treatment related questions.
